Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jane Wrigley
Observed name:
J. Wrigley
OpenAlex ID:
A5077781499
Combination strategies with checkpoint immunotherapy and inducers of immunogenic cell death (ICD) in immune competent syngeneic models
2016
·
A. McKenzie
, N. Papadopoulou
, et al.
·
European Journal of Cancer
·
2
Abstract A010: Interrogation of checkpoint inhibitors in bioluminescent orthotopic syngeneic models of hepatocellular carcinoma
2018
·
Nektaria Papadopoulou
, Louise Wainwright
, et al.
·
Molecular Cancer Therapeutics
·
1
Abstract 1060: Establishment of a panel of prostate patient derived xenograft (PDX) models and evaluation of anti-androgen therapy
2019
·
Jason Davis
, Anthony Oakden
, et al.
·
Cancer Research
Abstract 87: Recapitulating the orthotopic tumor microenvironment using bioluminescent syngeneic models in immune competent mice for checkpoint inhibitor interrogation
2019
·
Joyce Afrakoma Obeng
, Maya Jetha
, et al.
·
Cancer Research
Abstract 1060: Establishment of a panel of prostate patient derived xenograft (PDX) models and evaluation of anti-androgen therapy
2019
·
Jason Davis
, Anthony Oakden
, et al.
·
Tumor Biology
Abstract 87: Recapitulating the orthotopic tumor microenvironment using bioluminescent syngeneic models in immune competent mice for checkpoint inhibitor interrogation
2019
·
Joyce Afrakoma Obeng
, Maya Jetha
, et al.
·
Tumor Biology
Abstract 5033: Patient-derived xenograft screening in a three-dimensional tumor growth assay incorporating stromal elements to recapitulate the human tumor microenvironment
2018
·
Simon Jiang
, Jane Wrigley
, et al.
·
Cancer Research
Abstract A009: Evaluation of hormonal therapy in a panel of prostate patient-derived xenograft models and comparison to standard cell line models
2018
·
Nektaria Papadopoulou
, Louise Woolley
, et al.
·
Molecular Cancer Therapeutics
Abstract A213: Three-dimensional tumor growth assay for patient-derived tissue and cell line models incorporating stromal elements for screening
2018
·
Simon Jiang
, Jane Wrigley
, et al.
·
Molecular Cancer Therapeutics
Abstract 1829: Evaluation of checkpoint inhibitors on tumour infiltrating immune cells in the orthotopic and metastatic tumour microenvironment using bioluminescent syngeneic cell line models
2017
·
Andrew McKenzie
, Nektaria Papadopoulou
, et al.
·
Cancer Research
Abstract 2824: Validation of a panel of patient-derived xenograft models for prostate caner and cell line models for preclinical drug evaluation
2017
·
Nektaria Papadopoulou
, Jane Wrigley
, et al.
·
Cancer Research
Abstract A140: Check point inhibitor modulation of tumor microenvironment at orthotopic and metastatic sites using bioluminescent syngeneic cell line models in immune competent mice
2016
·
Andrew McKenzie
, Nektaria Papadopoulou
, et al.
·
Cancer Immunology Research
Abstract 3994: Immune competent syngeneic models demonstrate additive effects of combination strategies using checkpoint immunotherapy and inducers of immunogenic cell death (ICD)
2016
·
Andrew Mckenzie
, Rajendra Kumari
, et al.
·
Cancer Research
Abstract 769: In vivo response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitors
2015
·
Andrew McKenzie
, Nektaria Papadopoulou
, et al.
·
Cancer Research
Abstract 765: Overcoming acquired EGFRi resistance in NSCLC with targeted beam irradiation in combination with targeted agents
2015
·
Andrew McKenzie
, Nektaria Papadopoulou
, et al.
·
Cancer Research
Abstract 4875: In vivo and in vitro generation and characterisation of EGFR-TKI resistance in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models of NSCLC with activating EGFR mutations
2014
·
Andrew McKenzie
, Nektaria Papadopoulou
, et al.
·
Cancer Research
Abstract A145: In vivo and in vitro generation and characterization of EGFR TKI resistance in a patient-derived and a cell line-derived xenograft model of NSCLC with activating EGFR mutations.
2013
·
Andrew J. McKenzie
, Aaron N. Cranston
, et al.
·
Molecular Cancer Therapeutics
Abstract A142: In vivo response and molecular characterization of a Caucasian NSCLC squamous cell carcinoma PDX sensitive to FGFR inhibitor.
2013
·
Andrew J. McKenzie
, Aaron N. Cranston
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
18
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type